Valeant Pharmaceuticals International Inc. (NYSE:VRX) had its price target reduced by research analysts at Morgan Stanley from $42.00 to $25.00 in a research report issued on Thursday. The brokerage currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Morgan Stanley’s price objective would suggest a potential upside of 38.89% from the stock’s current price.

A number of other equities analysts also recently issued reports on VRX. Rodman & Renshaw restated a “buy” rating and set a $90.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Thursday, July 28th. Jefferies Group restated a “buy” rating and set a $40.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Wednesday, August 10th. Guggenheim restated a “buy” rating and set a $55.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 11th. TD Securities restated a “buy” rating and set a $38.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Saturday, August 13th. Finally, Canaccord Genuity restated a “hold” rating and set a $28.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Monday, August 1st. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and a consensus price target of $40.18.

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International (NYSE:VRX) opened at 18.00 on Thursday. The firm’s market cap is $6.26 billion. Valeant Pharmaceuticals International has a 52-week low of $13.77 and a 52-week high of $119.87. The firm’s 50-day moving average price is $22.04 and its 200-day moving average price is $25.21.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $1.55 EPS for the quarter, missing the consensus estimate of $1.78 by $0.23. The firm earned $2.48 billion during the quarter, compared to the consensus estimate of $2.49 billion. Valeant Pharmaceuticals International had a negative net margin of 22.17% and a positive return on equity of 41.02%. Valeant Pharmaceuticals International’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.74 earnings per share. Equities research analysts expect that Valeant Pharmaceuticals International will post $5.63 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the stock. Riggs Asset Managment Co. Inc. raised its stake in Valeant Pharmaceuticals International by 1.4% in the second quarter. Riggs Asset Managment Co. Inc. now owns 14,044 shares of the specialty pharmaceutical company’s stock worth $283,000 after buying an additional 200 shares during the last quarter. Capstone Asset Management Co. boosted its position in Valeant Pharmaceuticals International by 1.4% in the third quarter. Capstone Asset Management Co. now owns 26,408 shares of the specialty pharmaceutical company’s stock valued at $648,000 after buying an additional 360 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Valeant Pharmaceuticals International by 6.7% in the second quarter. Tower Research Capital LLC TRC now owns 6,405 shares of the specialty pharmaceutical company’s stock valued at $129,000 after buying an additional 402 shares during the last quarter. Allen Investment Management LLC boosted its position in Valeant Pharmaceuticals International by 4.1% in the first quarter. Allen Investment Management LLC now owns 12,411 shares of the specialty pharmaceutical company’s stock valued at $326,000 after buying an additional 493 shares during the last quarter. Finally, Breton Hill Capital Ltd. boosted its position in Valeant Pharmaceuticals International by 3.7% in the second quarter. Breton Hill Capital Ltd. now owns 17,379 shares of the specialty pharmaceutical company’s stock valued at $350,000 after buying an additional 627 shares during the last quarter. Institutional investors own 64.39% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.